

Supplemental Table S5. Change of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) during the intervention period from baseline in subgroups stratified by selected baseline characteristics, the Minnesota Green Tea Trial, 2009-2015

Stratifying variable at baseline	ALT (U/L)					<i>P</i> ^b	AST (U/L)					<i>P</i> ^c
	Placebo		GTE		<i>P</i> ^b		Placebo		GTE		<i>P</i> ^b	
	No.	Mean (95% CI) ^a	No.	Mean (95% CI) ^a			No.	Mean (95% CI) ^a	No.	Mean (95% CI) ^a		
Total triglyceride level (mg/dl)						0.9					0.72	
<150	409	-0.9 (-2.3-0.5)	414	3.4 (2.0-4.8)	<0.0001		409	-0.5 (-1.6-0.4)	414	2.3 (1.3-3.4)	<0.0001	
≥150	64	1.0 (-1.0-2.9)	46	5.4 (3.3-7.5)	0.001		64	1.1 (-0.4-2.5)	46	3.6 (2.1-5.2)	0.01	
<i>P</i> ^d		0.03		0.03				0.01		0.07		
Blood cholesterol level (mg/dl)						0.71					0.72	
<200	189	-1.0 (-2.5-0.5)	197	3.6 (2.1-5.1)	<0.0001		189	-0.4 (-1.5-0.7)	197	2.5 (1.4-3.6)	<0.0001	
200-240	212	-0.6 (-2.1-0.9)	200	3.4 (1.8-4.9)	<0.0001		212	-0.4 (-1.5-0.7)	200	2.5 (1.4-3.6)	<0.0001	
>240	72	0.8 (-1.1-2.7)	63	4.7 (2.8-6.7)	0.001		72	0.3 (-1.1-1.7)	63	2.6 (1.1-4.0)	0.01	
<i>P</i> ^d		0.7		0.09				0.75		0.91		
Current Use of Aspirin						0.74					0.85	
No	367	-0.4 (-2.2-1.4)	376	5.4 (3.6-7.2)	<0.0001		367	-0.1 (-1.4-1.3)	376	3.8 (2.5-5.2)	<0.0001	
Yes	140	-0.6 (-2.6-1.3)	136	5.4 (3.5-7.4)	<0.0001		140	-0.3 (-1.8-1.1)	136	3.7 (2.2-5.2)	<0.0001	
<i>P</i> ^c		0.68		0.96				0.59		0.79		
Current Use of Non-aspirin NSAID						0.003					0.1	
No	169	-0.04 (-1.8-1.7)	158	6.3 (4.3-8.2)	<0.0001		169	-0.4 (-1.3-1.3)	158	4.2 (2.8-5.7)	<0.0001	
Yes	338	-1.3 (-3.2-0.6)	354	5.0 (3.2-6.8)	<0.0001		338	-0.5 (-1.9-1.0)	354	3.6 (2.4-5.0)	<0.0001	
<i>P</i> ^d		0.03		0.04				0.31		0.19		

(Supplemental Table S5 continued)

Current Use of Acetaminophen												0.99
No	370	-0.8 (-2.5-1.0)	362	5.3 (3.6-7.1)	<0.0001	0.23	370	-0.3 (-1.6-1.1)	362	3.7 (2.3-5.0)	<0.0001	
Yes	137	0.4 (-1.5-2.4)	150	5.5 (3.5-7.4)	<0.0001		137	0.1 (-1.3-1.6)	150	4.1 (2.6-5.5)	<0.0001	
<i>P</i> ^d		0.06		0.82				0.41		0.4		
Current Use of Statin						0.67						0.36
No	401	-0.4 (-2.2-1.4)	397	5.3 (3.6-7.1)	<0.0001		401	-0.1 (-1.9-1.2)	397	3.7 (2.4-5.0)	<0.0001	
Yes	106	-0.6 (-2.6-1.4)	115	5.6 (3.6-7.6)	<0.0001		106	-0.4 (-1.9-1.2)	115	4.1 (2.6-5.6)	<0.0001	
<i>P</i> ^d		0.82		0.72				0.63		0.44		

GTE, green tea extract; BMI, body mass index; CI, confidence interval; NASID, Nonsteroidal anti-inflammatory drug; *COMT*, catechol-*O*-methyltransferase; All means are from Least Squares Means.

^a Least squares mean changes in the 12-month treatment period over baseline level.

^b 2-sided *P* values were derived from generalized linear mixed models comparing the changes of liver enzyme (ALT or AST) during the intervention period from baseline of women in the GTE group to the corresponding changes in the placebo group after adjustments for age, BMI, smoking status and level of education.

^c 2-sided *P* values were derived from the same model assessing the interaction between the intervention (GTE or placebo) and the stratifying variables on the liver enzyme (ALT or AST) with the same adjustments.

^d 2-sided *P* values were derived from the same model comparing the differences in changes of liver enzyme (ALT or AST) from baseline among different levels of stratifying variables within the GTE or placebo group.